Mizuho Securities Keeps a Sell Rating on Eagle Pharmaceuticals

By Ryan Adsit

In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Sell rating on Eagle Pharmaceuticals (NASDAQ: EGRX), with a price target of $40. The company’s shares closed yesterday at $52.38, close to its 52-week low of $45.05.

According to TipRanks.com, Koffler is a 5-star analyst with an average return of 12.7% and a 49.0% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Adamas Pharmaceuticals, and Jazz Pharmaceuticals.

Eagle Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $63.33.

The company has a one-year high of $97.15 and a one-year low of $45.05. Currently, Eagle Pharmaceuticals has an average volume of 247.9K.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Sander Flaum, a Director at EGRX sold 2,340 shares for a total of $126,220.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eagle Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the provision of injectable products. Its activities include development and commercialization of pharmaceutical products for the treatment of areas such as critical care, orphan diseases, and oncology. The company was founded by Scott L.